In patients with urothelial carcinoma (UC), the relationship between PD-L1 and PD-1 leads to the inaction of T cells across the microenvironment and the evasion of host immune response. A hospital-based observational study from Anushweta Singh, MD, and colleagues published in Cureus investigated the role of PD-L1 in patients with UC and analyzed its expression using histomorphological parameters. ...
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
Dr. Prasad provides updates on the positive DOR data observed with UGN-102 for LG-IR-NMIBC in the ENVISION trial.
UroGen began the process of a rolling New Drug Application to the FDA for mitomycin as a treatment for patients with NMIBC.
Dr. Li describes his post hoc analysis and findings regarding patients with BCG–unresponsive, high-risk NMIBC in ...
Dr. Li details the final results of CORE-001, a phase-2, single arm study of cretostimogene combined with pembrolizumab.
Urinary tumor DNA predicts residual bladder cancer pre-surgery, improving assessments and treatment, ASCO 2024 study finds
The CORE-001 trial began in 2020 to study the breakthrough therapy cretostimogene with pembrolizumab for high-risk NMIBC.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.